June’s $25.7B M&A haul caps biopharma’s record-breaking first half
· amanda lanier
AI Briefing
- • Biopharma deal value reached $170.11 billion through June 2026, surpassing previous records.
- • June's deal value was $34.59 billion, the second-strongest month of H1 2026.
- • May's deal value was $41.95 billion, the strongest month of H1 2026.
Source Summary
Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion.
Advertisement